Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clene Inc.CLNN · Entity 7166 | Chief Finance Officer | November 04, 2021 | November 04, 2021 |
| MetaVia Inc.NRBO · Entity 7947 | Director | January 13, 2020 | January 15, 2020 |
| Opus Genetics, Inc.RNN · Entity 5892 | Chief Financial Officer | January 20, 2017 | January 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clene Inc.
Report date November 04, 2021 · Filed November 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.74 · Expires 2031-11-04 | Direct | 62,500 |
Reported balance
After 2021-11-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-04 · Grant · Acquired 62,500 · Balance 62,500 F1: This option was granted on November 4, 2021 as an option for 62,500 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $4.74 per share. The options vest with respect to the first 25% of such shares on November 4, 2022 and then in 36 equal installments of Common Stock on the last day of each calendar month, beginning November 30, 2022, until such shares are fully vested |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on November 4, 2021 as an option for 62,500 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $4.74 per share. The options vest with respect to the first 25% of such shares on November 4, 2022 and then in 36 equal installments of Common Stock on the last day of each calendar month, beginning November 30, 2022, until such shares are fully vested
MetaVia Inc.
Report date January 13, 2020 · Filed January 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2030-01-12 | Direct | 60,000 |
Reported balance
After 2020-01-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-13 · Grant · Acquired 60,000 · Balance 60,000 F1: The option vests in 36 equal monthly installments beginning on 2/13/2020, such that the option will be fully vested on the third anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 36 equal monthly installments beginning on 2/13/2020, such that the option will be fully vested on the third anniversary of the date of grant.
Opus Genetics, Inc.
Report date January 20, 2017 · Filed January 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2027-01-20 | Direct | 300,000 |
Reported balance
After 2017-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-20 · Grant · Acquired 300,000 · Balance 300,000 F1: One quarter of the option vests and becomes exercisable on January 20, 2018, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 63,000 |
Reported balance
After 2017-01-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-20 · Grant · Acquired 63,000 · Balance 63,000 F2: Each restricted stock unit represents a contingent right to receive one share of common stock. F3: The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: One quarter of the option vests and becomes exercisable on January 20, 2018, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
F3: The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2021 Filed Nov 4, 2021 18:58 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 62,500 | $0.00 Strike: $4.74 | $0.00 |
DisclosureSEC source: 0001562180-21-006856 · primarydocument.xml · derivative · entry 1 Jeong Tae Heum · CIK 0001317190 · Chief Finance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2031-11-04 F1 · derivative.exercise_date: This option was granted on November 4, 2021 as an option for 62,500 shares of Common Stock under the Clene Inc. 2020 Stock Plan at an exercise price of $4.74 per share. The options vest with respect to the first 25% of such shares on November 4, 2022 and then in 36 equal installments of Common Stock on the last day of each calendar month, beginning November 30, 2022, until such shares are fully vested Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 17:21 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 20,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001562180-21-003064 · primarydocument.xml · derivative · entry 1 Jeong Tae Heum · CIK 0001317190 · Chief Finance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-04-30 F1 · shares: This option was granted on April 30, 2021 under the Clene Inc. 2020 Stock Plan. The options vest in 24 equal installments on the last day of each calendar month, beginning May 31,2021, until fully vested F1 · derivative.exercise_date: This option was granted on April 30, 2021 under the Clene Inc. 2020 Stock Plan. The options vest in 24 equal installments on the last day of each calendar month, beginning May 31,2021, until fully vested Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:51 UTC | Clene Inc. CLNN · Entity 7166 | GrantStock Options (Right to buy) · Derivative | 130,000 | $6.55 Strike: $6.55 | $851,500.00 |
DisclosureSEC source: 0001562180-21-000886 · primarydocument.xml · derivative · entry 1 Jeong Tae Heum · CIK 0001317190 · Chief Finance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2031-02-01 F1 · derivative.exercise_price: This option was granted on February 1, 2021 as an option for 130,000 shares of Common Stock under the Company 2020 Stock Plan, at an exercise price of $6.55 per share. The option vests in 24 equal installments of Common Stock on the last day of each calendar month, beginning on February 28th, 2021, until such shares are fully vested. F1 · shares: This option was granted on February 1, 2021 as an option for 130,000 shares of Common Stock under the Company 2020 Stock Plan, at an exercise price of $6.55 per share. The option vests in 24 equal installments of Common Stock on the last day of each calendar month, beginning on February 28th, 2021, until such shares are fully vested. F1 · price: This option was granted on February 1, 2021 as an option for 130,000 shares of Common Stock under the Company 2020 Stock Plan, at an exercise price of $6.55 per share. The option vests in 24 equal installments of Common Stock on the last day of each calendar month, beginning on February 28th, 2021, until such shares are fully vested. F1 · derivative.underlying_shares: This option was granted on February 1, 2021 as an option for 130,000 shares of Common Stock under the Company 2020 Stock Plan, at an exercise price of $6.55 per share. The option vests in 24 equal installments of Common Stock on the last day of each calendar month, beginning on February 28th, 2021, until such shares are fully vested. F1 · balance_after: This option was granted on February 1, 2021 as an option for 130,000 shares of Common Stock under the Company 2020 Stock Plan, at an exercise price of $6.55 per share. The option vests in 24 equal installments of Common Stock on the last day of each calendar month, beginning on February 28th, 2021, until such shares are fully vested. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 19:12 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantNon-qualified stock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001683168-20-000159 · ownership.xml · derivative · entry 1 Jeong Tae Heum · CIK 0001317190 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-01-12 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments beginning on 2/13/2020, such that the option will be fully vested on the third anniversary of the date of grant. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 17:52 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantRestricted Stock Units · Derivative | 63,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002737 · form4.xml · derivative · entry 2 Jeong Tae Heum · CIK 0001317190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments on the last business day in February, beginning February 28, 2018. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 17:52 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001140361-17-002737 · form4.xml · derivative · entry 1 Jeong Tae Heum · CIK 0001317190 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2027-01-20 F1 · derivative.exercise_date: One quarter of the option vests and becomes exercisable on January 20, 2018, and, thereafter, 1/36th of the remaining option vests in equal installments on the first business day of each month until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.